Bitcoin briefly surpassed $83,000 on October 19 but retreated to around $82,000 by early evening ET. This movement coincided with China reporting a stronger-than-expected 4.5% GDP growth in Q3, up from 4.3% in Q2, boosting market sentiment. Meanwhile, the Nasdaq Composite gained 1.1%, reflecting positive tech sector momentum, while the S&P 500 rose 0.4% and the Dow Jones fell slightly by 0.1%. Despite the headline GDP growth, China showed weaker domestic indicators such as a modest 1.1% rise in retail sales and a significant 20.6% drop in real estate investment for the first nine months of 2026. These mixed signals suggest cautious optimism in global markets.
Bitcoin's recent price movement comes as 46 out of 50 major cryptocurrencies on Pluang rose today, showing broad market strength. For readers following Bitcoin, here is Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: SAND (The Sandbox) rose 5.04% to Rp1.065 with a 44% Sell / 56% Buy order split, XTZ (Tezos) gained 4.85% to Rp5.401 with 0% Sell / 100% Buy activity, and GRT (The Graph) increased 4.73% to Rp428 despite 84% Sell / 16% Buy activity. Typical hold times on Pluang range from 99 to 123 days for these assets.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
